Good evening :)
Place Order
Add to Watchlist

Dr. Lal PathLabs Ltd

LALPATHLAB

Dr. Lal PathLabs Ltd

LALPATHLAB
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹29,090 cr, stock is ranked 275
Low RiskStock is 1.99x as volatile as Nifty
3,528.852.13% (-76.70)
3,528.852.13% (-76.70)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹29,090 cr, stock is ranked 275
Low RiskStock is 1.99x as volatile as Nifty

How to use scorecard? Learn more

Health CareHospitals & Diagnostic Centres
SmallcapWith a market cap of ₹29,090 cr, stock is ranked 275
Low RiskStock is 1.99x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
76.2515.430.52%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.226.550.48%

Forecast & Ratings

Detailed Forecast 
45%
Analysts have suggested that investors can buy this stock

from 20 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Dr Lal Pathlabs Private Limited is headquartered in Gurgaon, Haryana, India and is a medical laboratory operator.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 12.94%, vs industry avg of 10.02%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 3.41% to 3.72%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 12.42%, vs industry avg of 42.9%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue811.09939.921,088.141,249.371,385.411,632.602,139.962,058.602,295.812,362.90
Raw Materialssubtract172.92197.08226.03262.35298.70397.26502.25447.15451.421,654.40
Power & Fuel Costsubtract12.7813.5815.3215.7416.7418.6222.1125.9126.18
Employee Costsubtract136.83152.01180.75208.29242.64273.70364.94376.52424.57
Selling & Administrative Expensessubtract119.68149.29175.89208.79184.69176.29253.82268.27275.58
Operating & Other expensessubtract139.39162.90194.94214.59244.00279.12383.56409.20439.65
Depreciation/Amortizationsubtract28.2827.5433.0638.2272.8177.20108.11150.19143.60143.20
Interest & Other Itemssubtract0.500.700.840.8415.3116.0030.1837.5329.3627.40
Taxes & Other Itemssubtract68.5282.2390.59101.3784.56102.79130.15104.98147.72156.40
EPS19.2518.6520.5223.9027.1134.9941.3828.6542.8845.70
DPS2.453.004.506.0012.0020.0012.006.0018.0030.00
Payout ratio0.130.160.220.250.440.570.290.210.420.66

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 23PDF
May 17PDF
Feb 10PDF
+2 more
FY 2023

Annual report

PDF

Investor Presentation

May 11PDF
Nov 8PDF
Jul 28PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 8PDF
Jul 27PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareHospitals & Diagnostic Centres

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Dr. Lal PathLabs Ltd81.3215.430.52%
Apollo Hospitals Enterprise Ltd108.3813.300.24%
Max Healthcare Institute Ltd85.1510.710.16%
Fortis Healthcare Ltd73.295.130.17%

Price Comparison

Compare LALPATHLAB with any stock or ETF
Compare LALPATHLAB with any stock or ETF
LALPATHLAB
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Decreased Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has decreased by 1.52%

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding54.60%9.30%3.42%25.42%7.26%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun24.89%23.27%24.36%25.35%26.15%25.42%

Mutual Funds Holding Trend

Increased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 2.50%

Top 5 Mutual Funds holding Dr. Lal PathLabs Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
HDFC Flexi Cap Fund - Growth - Direct Plan

Growth
2.1287%0.94%0.16%27/58 (+4)
UTI Flexi Cap Fund - Growth - Direct Plan

Growth
1.3958%1.47%-0.09%46/70 (-3)
SBI Large & Midcap Fund - Growth - Direct Plan

Growth
0.7379%0.73%0.03%72/88 (-21)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Dr. Lal PathLabs Ltd

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

LALPATHLAB has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.52%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.17 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 20, 2024

Interim
Interim | Div/Share: ₹6.00

Dividend/Share

₹6.00

Ex DateEx Date

Aug 20, 2024

Cash Dividend

Ex DateEx DateJun 10, 2024

Final
Final | Div/Share: ₹6.00

Dividend/Share

₹6.00

Ex DateEx Date

Jun 10, 2024

Cash Dividend

Ex DateEx DateFeb 13, 2024

Interim 2
Interim 2 | Div/Share: ₹12.00

Dividend/Share

₹12.00

Ex DateEx Date

Feb 13, 2024

Cash Dividend

Ex DateEx DateAug 11, 2023

Final
Final | Div/Share: ₹6.00

Dividend/Share

₹6.00

Ex DateEx Date

Aug 11, 2023

Cash Dividend

Ex DateEx DateAug 11, 2023

Interim
Interim | Div/Share: ₹6.00

Dividend/Share

₹6.00

Ex DateEx Date

Aug 11, 2023

News & Opinions
Corporate
Dr Lal Pathlabs allots 93,900 equity shares under ESOP

Dr Lal Pathlabs has allotted 93,900 equity shares under Dr. Lal PathLabs Employee Stock Option Plan, 2022. Pursuant to the above allotment, the paid-up equity share capital of the Company increased to Rs 83,57,42,520/- divided into 8,35,74,252 equity shares of Rs 10/- each.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Board of Dr. Lal PathLabs recommends interim dividend

Dr. Lal PathLabs announced that the Board of Directors of the Company at its meeting held on 7 August 2024, inter alia, have recommended the interim dividend of Rs 6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Dr Lal Pathlabs consolidated net profit rises 28.81% in the June 2024 quarter

Net profit of Dr Lal Pathlabs rose 28.81% to Rs 106.40 crore in the quarter ended June 2024 as against Rs 82.60 crore during the previous quarter ended June 2023. Sales rose 11.26% to Rs 601.90 crore in the quarter ended June 2024 as against Rs 541.00 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales601.90541.00 11 OPM %28.2427.02 - PBDT184.60152.60 21 PBT149.90117.50 28 NP106.4082.60 29 Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Dr Lal PathLabs gains after Q1 PAT rises 29% YoY to Rs 108 cr

Revenue from operations increased 11.26% YoY to Rs 601.9 crore during the quarter. Profit before tax (PBT) stood at Rs 149.9 crore, up 27.57% as comapred with Rs 117.5 crore posted in same quarter last year. Total expenses increased 7.92% to Rs 472.6 crore in Q1 FY25 as compared with Rs 437.9 crore posted in corresponding quarter last year. Cost of material consumed stood at Rs 119.4 crore (up 5.57% YoY), employee benefit expenses was at Rs 116.6 crore (up 11.37% YoY), fees to collection centers/ channel partners was at Rs 83.7 crore (up 12.35% YoY) during the period under review. During the quarter EBITDA jumped to Rs 170 crore as compared with Rs 146 crore posted in same quarter last year, registering the growth of 16.2%. Meanwhile, the company's board declared interim dividend of Rs 6 per share for FY25. Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. The company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. As on 31 March 2023, the company has 277 clinical laboratories, 5,102 patient service centers (PSCs) and 10,938 pick-up points (PUPs).Powered by Capital Market - Live

2 months agoCapital Market - Live

Dr. Lal Pathlabs and 2 other stocks with White Marubozu Pattern

2 months agoEconomic Times
Corporate
Dr. Lal PathLabs to declare Quarterly Result

Dr. Lal PathLabs will hold a meeting of the Board of Directors of the Company on 7 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Technical Breakout Stocks: Alembic Pharma, Dr Lal PathLabs and Zydus Wellness hit 52-week highs; what should traders do? - Market Roundup

2 months agoEconomic Times
LIVE | On The Record: Dr Lal PathLabs | 75 Years Of Legacy | Exclusive | N18L | CNBC TV18
4 months agoCNBC-TV18

Dr. Lal Pathlabs Q4 Results Review - Subdued Volume Outlook: Yes Securities

4 months agoBloomberg Quint

Trade setup for Thursday: 15 things to know before opening bell

5 months agoMoneycontrol